within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BC06_Dexlansoprazole;

model Dexlansoprazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 3.1666666666666667e-06,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 0.040299999999999996,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016,
    Tlag = 3600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dexlansoprazole</td></tr><tr><td>ATC code:</td><td>A02BC06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>40.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>11.4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dexlansoprazole is a proton pump inhibitor (PPI) used for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and other acid-related disorders. It is the R-enantiomer of lansoprazole and is approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration of dexlansoprazole delayed-release capsules.</p><h4>References</h4><ol><li><p>Parekh, PJ, et al., &amp; Johnson, DA (2014). Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium). <i>Expert opinion on pharmacotherapy</i> 15(9) 1215–1222. DOI:<a href=\"https://doi.org/10.1517/14656566.2014.911841\">10.1517/14656566.2014.911841</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24749891/\">https://pubmed.ncbi.nlm.nih.gov/24749891</a></p></li><li><p>Miura, M, et al., &amp; Suzuki, T (2006). Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. <i>International journal of clinical pharmacology and therapeutics</i> 44(12) 605–613. DOI:<a href=\"https://doi.org/10.5414/cpp44605\">10.5414/cpp44605</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17190370/\">https://pubmed.ncbi.nlm.nih.gov/17190370</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A02BC06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dexlansoprazole;
